Want to see IPSC full AI Analyst Report?
Top Page
Century Therapeutics
(NASDAQ:IPSC)
Select Model
Select Model
Rating:49Neutral
Price Target:
$1.50
▼(-29.91% Downside)
Action:Reiterated
Date:10/09/26
The score is held back primarily by weak financial performance (ongoing losses and substantial cash burn) and a bearish technical trend (price below major moving averages with negative MACD). Offsetting these risks, corporate events around pipeline and regulatory progress are positive, and the balance sheet leverage appears modest, but valuation support is limited due to negative earnings and no dividend.
Positive Factors
CNTY-813 clinical and manufacturing progress
CNTY-813’s replicated preclinical performance and clinical-scale manufacturing evidence reduce key execution risks as the program approaches first-in-human testing. Demonstrated durability, engraftment, and storage resilience could support a scalable product model if clinical outcomes validate the therapy.
Negative Factors
No current revenue and continuing losses
The return to zero trailing revenue shows that Century has not established a recurring commercial or collaboration revenue base. Continued net losses mean pipeline development remains dependent on external financing or future approvals, limiting current earnings visibility and financial self-sufficiency.
Read all positive and negative factors
Positive Factors
Negative Factors
CNTY-813 clinical and manufacturing progress
CNTY-813’s replicated preclinical performance and clinical-scale manufacturing evidence reduce key execution risks as the program approaches first-in-human testing. Demonstrated durability, engraftment, and storage resilience could support a scalable product model if clinical outcomes validate the therapy.
Read all positive factors
Century Therapeutics (IPSC) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$266.18M
Dividend YieldN/A
Average Volume (3M)685.01K
Price to Earnings (P/E)―
Beta (1Y)1.80
Revenue Growth-100.00%
EPS Growth-219.52%
CountryUS
Employees78
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.04
Shares Outstanding181,075,320
10 Day Avg. Volume1,039,222
30 Day Avg. Volume685,006
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.54
Price to Sales (P/S)0.79
P/FCF Ratio-0.82
Enterprise Value/Market Cap1.59
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-16.57
Enterprise Value/Ebitda-4.57
Forecast
1Y Price Target
$5.90Price Target Upside175.70% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.52
Revenue Forecast (FY)N/A
Century Therapeutics Business Overview & Revenue Model
Company Description
Century Therapeutics, Inc. is a biotechnology company dedicated to pioneering allogeneic cell therapies for a range of cancers, specifically solid tumors and hematological malignancies. The firm's foremost clinical program is CNTY-101, an allogene...
How the Company Makes Money
Century Therapeutics’ ability to generate revenue is primarily tied to (1) collaboration and licensing arrangements and (2) potential future product sales if its therapeutic candidates receive regulatory approval.
1) Collaboration/licensing reven...
Century Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
64
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 109.16M | 6.59M | 2.23M | 5.20M | 0.00 |
| Gross Profit | -25.53M | 96.06M | 6.59M | 2.23M | 5.20M | -4.58M |
| EBITDA | -92.50M | 3.45M | -111.47M | -121.21M | -121.20M | -90.76M |
| Net Income | -109.79M | -9.58M | -126.57M | -136.67M | -130.93M | -95.82M |
Balance Sheet | ||||||
| Total Assets | 287.01M | 223.70M | 353.22M | 360.69M | 486.54M | 437.38M |
| Cash, Cash Equivalents and Short-Term Investments | 119.71M | 117.11M | 189.29M | 172.74M | 315.50M | 222.88M |
| Total Debt | 34.63M | 43.56M | 53.83M | 48.17M | 49.41M | 25.12M |
| Total Liabilities | 54.66M | 64.77M | 191.85M | 175.94M | 183.81M | 41.14M |
| Stockholders Equity | 232.34M | 158.94M | 161.36M | 184.75M | 302.74M | 396.24M |
Cash Flow | ||||||
| Free Cash Flow | -88.53M | -104.72M | -110.29M | -102.08M | -16.55M | -133.97M |
| Operating Cash Flow | -86.74M | -103.88M | -110.14M | -88.35M | 14.05M | -89.00M |
| Investing Cash Flow | -47.82M | 107.50M | 47.48M | 61.13M | -13.13M | -298.34M |
| Financing Cash Flow | 126.99M | 173.00K | 74.56M | -9.72M | 27.16M | 417.77M |
Century Therapeutics Technical Analysis
Negative
2.14
Price Trends
1.82
Negative
2.02
Negative
2.10
Negative
Market Momentum
-0.13
Negative
42.48
Neutral
65.73
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IPSC, the sentiment is Negative. The current price of 2.14 is above the 20-day moving average (MA) of 1.54, above the 50-day MA of 1.82, and above the 200-day MA of 2.10, indicating a bearish trend. The MACD of -0.13 indicates Negative momentum. The RSI at 42.48 is Neutral, neither overbought nor oversold. The STOCH value of 65.73 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IPSC.
Century Therapeutics Risk Analysis
Century Therapeutics disclosed 90 risk factors in its most recent earnings report. Century Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Century Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $41.50M | 3.14 | 83.42% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $266.18M | -1.32 | -52.76% | ― | -100.00% | -219.52% | |
42 Neutral | $10.14M | -0.13 | -1270.11% | ― | ― | 69.34% | |
42 Neutral | $6.96M | -0.15 | 3398.40% | ― | ― | 15.37% | |
41 Neutral | $9.58M | -0.41 | -456.35% | ― | ― | 9.68% |
* Healthcare Sector Average
IPSC
Century Therapeutics
1.47
0.90
157.89%
TPST
Tempest Therapeutics
0.60
-9.93
-94.30%
ATNM
Actinium Pharmaceuticals
1.32
-0.20
-13.16%
LTRN
Lantern Pharma
0.64
-3.48
-84.44%
CALC
CalciMedica
1.02
-14.93
-93.61%
Century Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Century Therapeutics advances CNTY-813 islet therapy program
Positive
Oct 2, 2026
On October 2, 2026, Century Therapeutics presented new nonclinical data on its iPSC-derived islet replacement therapy CNTY-813 at the European Association for the Study of Diabetes meeting in Milan, underscoring the program’s steady progress...
Business Operations and StrategyExecutive/Board Changes
Century Therapeutics Adds Director, Advances Cell Therapy Pipeline
Positive
Sep 9, 2026
On September 9, 2026, Century Therapeutics expanded its board from six to seven members and appointed veteran biotech executive Joseph Truitt as an independent Class I director, with a term running to the 2028 annual meeting. Truitt, who also join...
Business Operations and StrategyFinancial Disclosures
Century Therapeutics Reports Q2 Results, Pipeline Advancements
Positive
Aug 12, 2026
Century Therapeutics reported its second-quarter 2026 results on August 12, 2026, highlighting progress across its iPSC-derived cell therapy pipeline for autoimmune diseases and cancer, including type 1 diabetes and B-cell-mediated conditions. The...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.